a single-dose vial for subcutaneous injection at 45 mg/0.5 mL and a single-dose vial for intravenous infusion at 130 mg/26 mL ...

8 In the 12-week controlled period of the study, 903 patients were randomized to receive subcutaneous injections of ustekinumab (45 mg or 90 mg at weeks 0 and 4) or of high-dose etanercept (50 ...

Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. About Otulfi Otulfi (ustekinumab-aauz) is a human monoclonal ...